Genmab — Juli 2014
-
Content not found
Terrapinn is a global events company. Our events promote innovation and technology that changes people's lives. We partner with the world's leading companies and innovators to make a difference.
(www.terrapinn.com)
-
-
tak for det gentogen
-
Var sikker på at det var Rituxan+Idealisib men kan godt læse nu at det ser ud til at være idelalisib i mono
-
Det er vel fordi det er færdigrekruteret det data studie?
-
Har lige tjekket, de trak også 35% der
-
These data in CLL support Gilead’s plans for regulatory filings for idelalisib in the United States and European Union. On September 11, 2013, Gilead submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for idelalisib for the treatment of refractory indolent non-Hodgkin’s lymphoma (iNHL). Following Gilead’s NDA submission for iNHL, FDA granted idelalisib a Breakthrough Therapy designation for CLL in relapsed patients based on results from Study 116. Gilead is now
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind